Reacción acneiforme como efecto adverso del apremilast / Acneiform reaction as an adverse effect of apremilast
Dermatol. argent
; 27(1): 28-30, ene.-mar. 2021. il
Article
in Es
| LILACS, BINACIS
| ID: biblio-1361644
Responsible library:
AR144.1
Localization: AR144.1; 616.5/25
RESUMEN
El apremilast es un fármaco inhibidor de la fosfodiesterasa-4 que modula, a nivel intracelular, la expresión de citoquinas involucradas en la patogenia inflamatoria de la psoriasis. Su uso está indicado en la psoriasis en placas moderada y severa, con buenos resultados clínicos. Los principales efectos adversos son gastrointestinales y, en menos del 2% de los pacientes, dermatológicos, con exantema y foliculitis. Se presenta el caso de un paciente de 42 años que, luego de tomar el apremilast, desarrolló lesiones faciales que correspondieron clínica e histopatológicamente a una reacción acneiforme, con evolución favorable y resolución total del cuadro posterior a la suspensión del medicamento.
ABSTRACT
Apremilast is a phosphodiesterase-4 inhibitor that modulates the intracellular expression of cytokines, which are involved in the pathogenesis of psoriasis. Apremilast is indicated in moderate to severe plaque psoriasis, and it has shown good clinical results. The main adverse effects occur at a gastrointestinal level, and in less than 2% at the dermatologic level with exanthema and folliculitis. We present a 42-year-old patient that developed facial lesions after taking apremilast. The facial lesions were clinically and histopathologically correspond to an acneiform eruption. The patient evolved favorably and fully recovered after suspending apremilast.
Key words
Full text:
1
Index:
LILACS
Main subject:
Psoriasis
/
Thalidomide
Limits:
Adult
/
Humans
/
Male
Language:
Es
Journal:
Dermatol. argent
Journal subject:
DERMATOLOGIA
Year:
2021
Type:
Article